Pharmaseed Appoints Dr. Ilan Winkler as its new CEO Pharmaseed Appoints Dr. Ilan Winkler as its new CEO

Pharmaseed Appoints Dr. Ilan Winkler as its new CEO



Pharmaseed Appoints Dr. Ilan Winkler as its new CEO

NESS ZIONA, Israel, January 18, 2020 — Pharmaseed, Israel’s largest GLP-certified preclinical CRO specializing in translational and regenerative studies today announced the appointment of Ilan Winkler, its former VP of Business development as its new CEO.

Dr. Winkler has led the business development of Pharmaseed in the past 6 years, leading it’s expansion and moving into new areas such as cannabis and toxicology and gaining several new clients from the global pharma industry.

He has over 15 years of hands-on experience in the pharmaceutical and drug-development industry, specializing in bio-pharmaceuticals, preclinical studies, pharmacokinetics and the development of new drugs. In his former position Dr. Winkler served as a VP Preclinical Development at LipoCure.

Dr. Winkler has published numerous scientific papers and patents, mainly concerning the development of therapeutic agents for treating disorders of the central nervous system. Dr. Winkler earned his Ph.D. at the Hebrew University of Jerusalem School of Pharmacy.

For more information on how we can help you
move your drug or device along the development pathway.
Contact Us